Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 6/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8746105 | 0.91 | HDAC1 (0.54) | LTA4HMAOAMAOBHDAC1NPC1 | |
| SCHEMBL8746082 | 0.90 | HDAC1 (0.56) | LTA4HMAOAMAOBHDAC1NPC1 | |
| SCHEMBL8746072 | 0.90 | HDAC1 (0.56) | LTA4HMAOAMAOBHDAC1NPC1 | |
| SCHEMBL3214637 | 0.87 | LTA4H (0.53) | LTA4HMAOAMAOBHDAC1NPC1 | |
| SCHEMBL6769982 | 0.86 | LTA4H (0.58) | LTA4HMAOAMAOBHDAC1NPC1 | |
| SCHEMBL329575 | 0.84 | ALOX5 (0.62) | LTA4HMAOAMAOBNPC1RAB9A | |
| SCHEMBL2489895 | 0.84 | LTA4H (0.51) | LTA4HHDAC1NPC1RAB9ADRD2 | |
| SCHEMBL30375479 | 0.82 | LTA4H (0.49) | LTA4HMAOBHDAC1PPARDCHRNB4 | |
| Indole SCHEMBL15320969 | 0.81 | ALOX5 (0.61) | LTA4HMAOAMAOBDRD2DRD3 | |
| SCHEMBL1388250 | 0.79 | MAOA (0.50) | LTA4HMAOAMAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2012135697-A2 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135697-A2 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-0758320-A1 | TRYPTAMINE DERIVATIVES AS 5-HT-1D RECEPTOR LIGANDS | Allelix Biopharmaceuticals Inc. (CA) | 1997-02-19 | — | — | EP | disclosed |
| US-5504101-A | TRYPTAMINE ANALOGS | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1996-04-02 | — | — | US | disclosed |
| WO-1995030655-A1 | TRYPTAMINE DERIVATIVES AS 5-HT-1D RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | LTA4H 2165/4885MAOA 1416/4885MAOB 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.